Investors

<p>Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.</p>

Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Secured Rights Issue 2018

On this page, you will find all relevant information that are published in connection with Immunicums’ proposed Rights Issue.

Press release

Immunicum AB (publ) Publishes Prospectus in Connection with Rights Issue and Directed Issue

23 November 2018
Download PDF
Finn prospekt och anmälningssedlar längre ned på sidan


Press release

Immunicum AB (publ) Clarifies Information Regarding Directed Issue

16 October 2018
Download PDF


Press release

Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel – a New and Innovative Cancer Immunotherapy

16 October 2018
Download PDF


Press release

Notice of extraordinary general meeting in Immunicum AB (publ)

16 October 2018
Download PDF


Prospectus

23 November 2018
Download PDF (only Swedish)


Frequently Asked Questions – Financing

2 November 2018
Download PDF


Extraordinary general meeting 2018

16 October 2018
Board resolution on directed share issue
Board proposal for resolution on directed share issue
Board resolution on rights issue
Board proposal for resolution on rights issue
Board’s report
Auditor’s statement (in Swedish)
Power of Attorney form